"Large-scale modelling of the human microbiome accounts for strain-specific drug metabolism"
Välkomna till en seminarieserie från institutionen för biologi och bioteknik − där vi möts för att lyssna på internationellt erkända föreläsare från intressanta och relevanta forskningsfält.
Efter seminariet finns det möjlighet att träffa Ines Thiele i break-out sessioner.
Om Ines Thiele
Ines Thiele is the principal investigator of the Molecular Systems Physiology group at the National University of Ireland, Galway.
Her research aims to improve the understanding of how diet influences
human health. Ines earned her PhD in bioinformatics from the University
of California, San Diego, in 2009. From 2009 until 2013, Ines was an
Assistant Professor at the University of Iceland. From April 2013 until
January 2019, she was an Associate Professor at the University of
Luxembourg. Since February 2019, Ines is a Professor for Systems
Biomedicine at the National University of Ireland, Galway. In 2013, Ines
Thiele received the ATTRACT fellowship from the Fonds National de la
Recherche (Luxembourg). In 2015, she was elected as EMBO Young
Investigator. In 2017, she was awarded the prestigious ERC starting
grant. She is an author of over 80 international scientific papers and
reviewer for multiple journals and funding agencies.
human microbiome influences the efficacy and safety of a wide variety
of commonly prescribed drugs, yet comprehensive systems-level approaches
to interrogate drug-microbiome interactions are lacking. I will present
a computational resource of human microbial genome-scale
reconstructions, deemed AGORA2, which accounts for 7,206 strains,
includes microbial drug degradation and biotransformation, and was
extensively curated based on comparative genomics and literature
searches. AGORA2 extends its predecessor, AGORA1, both in genome and
metabolic content coverage. I will show that the microbes can use the
drug molecules as carbon- and energy sources. Using microbial community
modelling with metagenomic data from a cohort of 616 colorectal cancer
patients and controls, I will show that the individual microbiomes have
different drug conversion potential in silico. This analysis revealed
that some drug activation capabilities were present in only a subset of
individuals, and that drug conversion potential correlate with clinical
parameters. Thus, AGORA2 paves the way towards personalised, predictive
analysis of host-drug-microbiome interactions.
via Zoom. Registrera dig för länk och lösenord.